Abortion Pill Deaths: Mystery Deepens
Women Who Took RU-486 Had Same Rare Bacterial Infection
WebMD News Archive
Nov. 30, 2005 - Four women in California who died of toxic shock syndrome
within a week of taking the controversial abortion pill RU-486 had the same
rare bacterial infection, federal officials have confirmed.
The deaths, which occurred between September 2003 and May of this year, were
due to the toxic effects of an infection with the highly lethal bacteria
Clostridium sordellii. Only 10 previous cases of fatal C.
sordellii infections had been reported, with eight of those occurring in
women who had given birth to live infants. One other was associated with an
abortion, and the remaining one was not associated with pregnancy at all.
The findings are reported in the Dec. 1 issue of The New England Journal
CDC investigator Marc Fischer, MD, MPH, tells WebMD that it is not yet clear
if there is something about the abortion pill that makes patients more
vulnerable to the rare infection.
He adds that officials with the CDC and the FDA, and outside experts, plan
to meet early next year to explore the issue.
"The fact that all four of these cases were due to the same rare
bacteria and that they all occurred in California certainly raises a lot of
questions," he says.
The RU-486 abortion pill is known by the brand name Mifeprex. Danco
Laboratories -- the maker of Mifeprex -- did not respond to a request for a
comment on the findings in time for the publication of this story.
The abortion pill was approved for use in the U.S. in 2000 for the
termination of early pregnancy, defined as seven weeks' duration or less.
According to Danco Laboratories, more than 460,000 doses of the medication
have been distributed in the U.S. since that time.
If the four deaths are the only ones that have occurred after using the
drug, it would suggest that less than one in 100,000 women who have used it to
induce abortions have died from infection. That is about 10 times higher than
the risk associated with surgical abortions performed early in pregnancy,
Harvard Medical School obstetrics and gynecology professor Michael F. Greene,
MD, tells WebMD.
But it is not clear if the actual risk is higher or lower than this, he
says, because there are so many questions that have yet to be answered.
"It is not clear to me or anybody else at this point if there is any
real biological or medical link between this method of pregnancy termination
and the risk of infection," he says.
The biggest mystery, the experts agree, is why all four cases occurred in a
single state. An FDA investigation found no evidence of drug contamination, and
it appears that Mifeprex is used with the same frequency and in the same way in
California as in other parts of the country, Fischer says.